Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus presents casdatifan kidney cancer trial data; second-line response rate 44%

Neutral Impact 3 of 5 other

Arcus Biosciences presented new data from its ARC-20 platform study of casdatifan, alone or in combination, for clear cell renal cell carcinoma, using a data cutoff of September 4, 2026. The filing reports response, progression and survival figures across first-line, second-line and late-line cohorts, with no unexpected safety signals cited for each regimen.

Key points

  • Second-line casdatifan plus cabozantinib (n=43): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
  • First-line casdatifan plus zimberelimab (n=30): cORR 50%, landmark PFS 69% at 12 months, primary progression 6.7%
  • Late-line casdatifan monotherapy (n=121): median overall survival 35 months, median PFS 13 months, cORR 36%

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECOct 20, 2026, 8:33 AM ET
Accession number0001724521-26-000047

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.